Ascomycin structure
|
Common Name | Ascomycin | ||
---|---|---|---|---|
CAS Number | 104987-12-4 | Molecular Weight | 792.008 | |
Density | 1.2±0.1 g/cm3 | Boiling Point | 868.3±75.0 °C at 760 mmHg | |
Molecular Formula | C43H69NO12 | Melting Point | 153-157ºC | |
MSDS | Chinese USA | Flash Point | 478.9±37.1 °C | |
Symbol |
GHS02, GHS07 |
Signal Word | Danger |
Use of AscomycinAscomycin(Immunomycin, FR-900520, FK520) is an ethyl analog of tacrolimus (FK506) with strong immunosuppressant properties. IC50 Value: 0.55 nM [1]Target: in vitro: When we used either CD4+CD8+ thymocytes or peripheral T cells activated by phorbol ester and ionomycin, the cell surface induction of CD5 was also partially blocked by CsA, FK-520 and rapamycin [2]. Ascomycinalso had a 3-fold lower immunosuppressive potency in a popliteal lymph node hyperplasia assay, resulting in an equivalent therapeutic index consistent with a common mechanistic dependence on calcineurin inhibition [3].in vivo: In 14-day studies, nephrotoxicity was not induced by continuous i.p. infusion of ascomycin at 10 mg/kg/day or daily oral administration (up to 50 mg/kg/day) in rats on a normal diet, nor by continuous i.v. infusion (up to 6 mg/kg/day) in rats on a low salt diet to enhance susceptibility [3]. |
Name | ascomycin |
---|---|
Synonym | More Synonyms |
Description | Ascomycin(Immunomycin, FR-900520, FK520) is an ethyl analog of tacrolimus (FK506) with strong immunosuppressant properties. IC50 Value: 0.55 nM [1]Target: in vitro: When we used either CD4+CD8+ thymocytes or peripheral T cells activated by phorbol ester and ionomycin, the cell surface induction of CD5 was also partially blocked by CsA, FK-520 and rapamycin [2]. Ascomycinalso had a 3-fold lower immunosuppressive potency in a popliteal lymph node hyperplasia assay, resulting in an equivalent therapeutic index consistent with a common mechanistic dependence on calcineurin inhibition [3].in vivo: In 14-day studies, nephrotoxicity was not induced by continuous i.p. infusion of ascomycin at 10 mg/kg/day or daily oral administration (up to 50 mg/kg/day) in rats on a normal diet, nor by continuous i.v. infusion (up to 6 mg/kg/day) in rats on a low salt diet to enhance susceptibility [3]. |
---|---|
Related Catalog | |
References |
Density | 1.2±0.1 g/cm3 |
---|---|
Boiling Point | 868.3±75.0 °C at 760 mmHg |
Melting Point | 153-157ºC |
Molecular Formula | C43H69NO12 |
Molecular Weight | 792.008 |
Flash Point | 478.9±37.1 °C |
Exact Mass | 791.481995 |
PSA | 178.36000 |
LogP | 3.81 |
Vapour Pressure | 0.0±0.6 mmHg at 25°C |
Index of Refraction | 1.546 |
Storage condition | −20°C |
Water Solubility | Soluble in DMSO at 65mg/ml; soluble in ethanol at 50mg/m; with warming. Very poorly soluble in water |
Symbol |
GHS02, GHS07 |
---|---|
Signal Word | Danger |
Hazard Statements | H225-H302 + H332-H319 |
Precautionary Statements | P210-P305 + P351 + P338 |
Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
Hazard Codes | Xn: Harmful; |
Risk Phrases | R20/21/22 |
Safety Phrases | 36/37 |
RIDADR | UN 1648 3 / PGII |
WGK Germany | 3 |
RTECS | KD4185000 |
HS Code | 29419090 |
Highly specific targeting of human leukocytes using gold nanoparticle-based biologically active conjugates.
J. Biomed. Nanotechnol. 10(7) , 1259-66, (2014) In this study we demonstrate for the first time a new approach for highly specific targeting of viable human leukocytes by functionalised gold nanoconjugates made on the basis of citrate-stabilised go... |
|
Effects of calcineurin inhibitors on an in vitro assay for chronic urticaria.
Clin. Exp. Allergy 35(5) , 554-9, (2005) Chronic urticaria is a common skin disorder, which causes considerable morbidity. In approximately 40% of cases, patients have an autoimmune disorder in which functional antibodies cause degranulation... |
|
The immunosuppressant cyclosporin A antagonizes human formyl peptide receptor through inhibition of cognate ligand binding.
J. Immunol. 177(10) , 7050-8, (2006) Cyclosporin A (CsA) is a fungus-derived cyclic undecapeptide with potent immunosuppressive activity. Its analog, cyclosporin H (CsH), lacks immunosuppressive function but can act as an antagonist for ... |
(1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-17-Ethyl-1,14-dihydroxy-12-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-propen-2-yl}-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatr ;icyclo[22.3.1.0]octacos-18-ene-2,3,10,16-tetrone |
immunomycin |
4H-Pyrrolo3,2-dpyrimidin-4-one,7-(2S,3S,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-pyrrolidinyl-1,5-dihydro |
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-8-ethyl-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone |
15,19-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone, 8-ethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-[(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-, (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)- |
(1R,9S,12S,13R,14S,17R,18Z,21S,23S,24R,25S,27R)-17-Ethyl-1,14-dihydroxy-12-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-propen-2-yl}-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatr ;icyclo[22.3.1.0]octacos-18-ene-2,3,10,16-tetrone |
(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-iMino-D-ribitol,iMMucillin H |
7-((2S,3S,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl)-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one |
Ascomycin |
changchuanmycin |
(1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-17-Ethyl-1,14-dihydroxy-12-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0]octacos-18-ene-2,3,10,16-tetrone |
7-[(2S,3S,4R,5R)-3,4-Dihydroxy-5-(hydroxymethyl)-2-pyrrolidinyl]-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one |
(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol |
Isopamphos |
Immucillin-H |
1,4-dideoxy-(1S)-1-C-(4-hydroxypyrrolo[3,2-d]pyrimidin-7-yl)-1,4-imino-D-ribitol |
15,19-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone, 8-ethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-[(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-, (3S,4R,5S,8R,9Z,12S,14S,15R,16S,18R,19R,26aS)- |
MFCD00467131 |
Fodosine |